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Abstract
Background: Nucleolin expressed at the cell surface is a binding protein for a variety of ligands implicated in
tumorigenesis and angiogenesis. By using a specific antagonist that binds the C-terminal RGG domain of nucleolin,
the HB-19 pseudopeptide, we recently reported that targeting surface nucleolin with HB-19 suppresses progression
of established human breast tumor cells in the athymic nude mice, and delays development of spontaneous
melanoma in the RET transgenic mice.
Methods: By the capacity of HB-19 to bind stably surface nucleolin, we purified and identified nucleolin partners at
the cell surface. HB-19 and related multivalent Nucant pseudopeptides, that present pentavalently or hexavalently
the tripeptide Lysψ(CH2N)-Pro-Arg, were then used to show that targeting surface nucleolin results in distinct
inhibitory mechanisms on breast, prostate, colon carcinoma and leukemia cells.
Results: Surface nucleolin exists in a 500-kDa protein complex including several other proteins, which we identified
by microsequencing as two Wnt related proteins, Ku86 autoantigen, signal recognition particle subunits SRP68/72,
the receptor for complement component gC1q-R, and ribosomal proteins S4/S6. Interestingly, some of the surface-
nucleolin associated proteins are implicated in cell signaling, tumor cell adhesion, migration, invasion, cell death,
autoimmunity, and bacterial infections. Surface nucleolin in the 500-kDa complex is highly stable. Surface nucleolin
antagonists, HB-19 and related multivalent Nucant pseudopeptides, exert distinct inhibitory mechanisms depending
on the malignant tumor cell type. For example, in epithelial tumor cells they inhibit cell adhesion or spreading and
induce reversion of the malignant phenotype (BMC cancer 2010, 10:325) while in leukemia cells they trigger a
rapid cell death associated with DNA fragmentation. The fact that these pseudopeptides do not cause cell death in
epithelial tumor cells indicates that cell death in leukemia cells is triggered by a specific signaling mechanism,
rather than nonspecific cellular injury.
Conclusions: Our results suggest that targeting surface nucleolin could change the organization of the 500-kDa
complex to interfere with the proper functioning of surface nucleolin and the associated proteins, and thus lead to
distinct inhibitory mechanisms. Consequently, HB-19 and related Nucant pseudopeptides provide novel therapeutic
opportunities in treatment of a wide variety of cancers and related malignancies.
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Nucleolin is a multifunctional DNA-, RNA- and pro-
tein-binding protein ubiquitously expressed in exponen-
tially growing eukaryotic cells. It is involved in
fundamental aspects of transcription, cell proliferation
and growth [1,2]. Nucleolin is found at several locations
in cells: in the nucleolus it controls many aspects of
DNA and RNA metabolism [3]; in the cytoplasm it
shuttles proteins into the nucleus and provides a post-
transcriptional regulation of strategic mRNAs [4,5]; and
on the cell surface it serves as an attachment protein for
several ligands from growth factors to microorganisms
[6-12]. In contrast to nuclear nucleolin, surface nucleo-
lin is glycosylated and is constantly induced in prolifer-
ating tumor and endothelial cells [6,13-15].
Surface nucleolin serves as a low affinity receptor for
HIV-1 and various growth factors that interact with its
C-terminal domain containing nine repeats of the tri-
peptide arginine-glycine-glycine, known as the RGG or
GAR domain [10,16-20]. Binding of these ligands results
in clustering of cell-surface nucleolin in lipid raft mem-
brane microdomains before endocytosis of the ligand-
nucleolin complex [10,17,19]. Accordingly, surface
nucleolin could shuttle ligands between the cell surface
and the nucleus thus act as a mediator for the extracel-
lular regulation of nuclear events [18,20,21]. Moreover,
ligand binding to surface nucleolin could generate high
transitory intracellular Ca
2+ membrane fluxes, and thus
initiate signal transduction events [13,22-25]. For an
example, the binding of P-selectin to human colon car-
cinoma cells is shown to induce tyrosine phosphoryla-
tion of surface nucleolin and formation of a signaling
complex containing nucleolin, phosphatidylinositol 3-
kinase (PI3-K) and p38 MAPK [26].
T h ei m p o r t a n c eo fc e l l - s u rface nucleolin in cancer
biology was recently highlighted by studies showing that
ligands of nucleolin play critical role in tumorigenesis
and angiogenesis [20,26-36]. Accordingly, we recently
reported that both of these events are suppressed by tar-
geting surface nucleolin with the HB-19 pseudopeptide,
ap o t e n ta n t a g o n i s tt h a tf o r ms an irreversible complex
with surface nucleolin [9,37]. By binding to the RGG
domain of nucleolin, HB-19 prevents binding of growth
factors to cells, triggers calcium entry into cells, inhibits
MAP kinase activation, and down-regulates surface
nucleolin without affecting nuclear nucleolin
[7,9,13,16,18,19,37]. In nude mice, we showed that HB-
19 treatment markedly suppresses the progression of
established human breast tumor cell xenografts, and in
some cases eliminates measurable tumors [37]. This
potent antitumoral effect in vivo is attributed to the
direct dual inhibitory action of HB-19 on tumor and
endothelial cells [37]. In a more relevant tumor model,
we showed that HB-19 treatment for several months
delays significantly the onset and frequency of sponta-
neous melanoma in RET mice, impairs tumor angiogen-
esis, and reduces metastasis while displaying no toxicity
to normal tissue [38]. Other groups have reported that
guanosine-rich quadruplex-forming oligodeoxynucleo-
tides (GROs), which interact with surface nucleolin and/
or intracellular nucleolin are promising agents for treat-
ment of cancer [39-41]. The aptamer AS1411 is the
most recent GRO that is currently being tested in Phase
II clinical trials. Finally, we recently reported that treat-
ment of G401 cells derived from a rhabdoid tumor of
the kidney and TIII cells derived from a malignant mel-
anoma can affect several criteria implicated in their
tumorigenic potential, such as restoration of contact
inhibition, reduction of colony formation in soft agar,
and impairment of tumorigenicity in mice [38,42]. Inter-
estingly, these changes are associated with a selective
down regulation of genes implicated in tumorigenesis.
Although nucleolin does not possess a hydrophobic
transmembrane domain to account for its expression
at the cell surface, it behaves as a typical membrane-
anchored receptor as demonstrated by its clustering
when intact cells are incubated with the anti-nucleolin
monoclonal antibody. This clustering occurs at the
external side of the plasma membrane and is depen-
dent on its indirect association with the intracellular
actin cytoskeleton [6]. An actin based motor protein,
the nonmuscle myosin heavy chain 9, could serve as a
physical linker between surface nucleolin and actin
[ 3 4 ] .H e r ew er e p o r tt h a ts u r face nucleolin exists in a
high molecular weight complex, referred to as 500-kDa
complex, in association with proteins partners known
for their implication in tumorigenesis, inflammation,
and bacterial infections. As the 500-kDa complex is
highly stable, targeting surface nucleolin could change
the organization of this complex and thus interfere
with the proper functioning of surface nucleolin and
the associated proteins. Indeed, by using HB-19 and
related multivalent Nucant pseudopeptides that present
pentavalently or hexavalently the tripeptide
Lysψ(CH2N)-Pro-Arg (Nucant 3, 6, 6L and 7) [43,44],
we show that such surface nucleolin antagonists exert
distinct inhibitory mechanisms depending on the
malignant tumor cell type. Accordingly, they inhibit
the production of pro-inflammatory cytokines by
human blood lymphocytes in response to stimulation
with inactivated Staphyloccocus aureus,i n h i b i ta d h e -
sion of human breast and prostate carcinoma cells,
impair spreading of human colon carcinoma cells, and
induce a selective cell killing in leukemia cells. Our
results further validate surface nucleolin as a strategic
target for an effective cancer drug.
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Cells and culture medium
Human breast (MDA-MB-231, MDA-MB-435 [37]),
prostate (LNCaP, from American Type Culture Collec-
t i o n ,A T C C ,R o c k v i l l e ,M D ) ,a n dc e r v i c a l( H e L a[ 4 5 ] )
epithelial cancer cells were grown in DMEM-glutamax
medium (Gibco Invitrogen, Cergy-Pontoise, France)
containing GlutaMAX™, 4.5 g/l glucose and supple-
mented with 10% heat-inactivated (56°C for 30 min)
fetal bovine serum (FBS; Hyclone, Thermo Fisher Scien-
tific, Inc). Human SW480 cells are derived from a grade
3-4 colon carcinoma, while the highly metastatic coun-
terpart SW620 is established from the lymph node of a
51-year-old Caucasian male. Both SW480 and SW620
cells (obtained from Francis Raul, IRCAD) are highly
tumorigenic in nude mice. They were cultured in D-
MEM, 10% FCS. The murine melanoma TIII cell line
was obtained from Armelle Prévost-Blondel [38]. Mur-
ine T29 lymphoma cells, obtained from Philippe Kastner
(CNRS, Strasbourg), have been established from Ik
L/L
tumors from mice carrying a hypomorphic mutation
(Ik
L/L) in the Ikaros gene encoding a transcription factor
that regulates lymphocyte differentiation, and acts also
as a tumor suppressor in T lymphocytes [46]. The T29
cells were cultured in RPMI medium containing 25 mM
Hepes pH 7.6, 1 mM sodium pyruvate, and 10% FCS.
Human leukemia cell lines, Jurkat (acute T cell leuke-
mia), HuT 78 (cutaneous T lymphocyte), RAJI (Burkitt
lymphoma), and HL60 (promyelocytic leukemia) were
cultured in RPMI-1640 medium (Gibco) containing Glu-
taMAX™, and supplemented with 10% heat-inactivated
FBS as described before [15]. The wild-type Chinese
hamster ovary cell line (CHO K1) was purchased from
American Type Culture Collection (ATCC; Rockville,
MD). The CHO LRP1-null cell line (CHO-13-5-1) was
kindly provided by D. Strickland [47]. They were cul-
tured in Ham’s F12K medium. All cells were cultured
with 10% (v/v) heat inactivated (56°C, 30 min) fetal
bovine serum (FBS) (Roche Molecular Biochemicals,
Indianapolis, IN) and 50 international units/mL penicil-
lin-streptomycin (Invitrogen). Cell death was monitored
conveniently by uptake of the trypan blue dye due to
plasma membrane permeability of dying and/or dead
cells.
Peptide constructs
The HB-19 pseudopeptide 5[Kψ(CH2N)PR-TASP, for
[Lysψ(CH2N)Pro-Arg]-template-assembled synthetic
peptide, binds specifically surface nucleolin and blocks
its function [9,16,37]. The template in HB-19, presents
pentavalently the tripeptide 5[Kψ(CH2N)PR where
(CH2N) represents a reduced peptide bond between
lysine and proline residues. The synthesis of HB-19 and
biotinylated HB-19 (HB-19/Btn) used for the recovery of
surface nucleolin were as described previously [16,48].
Other peptide constructs similar to HB-19 are referred
to as Nucant for Nucleolin antagonist. They present the
pseudo-tripeptide Lysψ(CH2N)-Pro-Arg pentavalently
(N3) or hexavalently (N6, N6L, N7) as described (Table
1; Additional file 1, Figure S1) [43,44,49]. N3, N6, N7,
and the biotinylated N3 and N7 were synthesized by
Jean Paul Briand, IBMC-CNRS, Strasbourg [43]. N6L
was kindly provided by R. Zimmer (ImmuPharma). All
peptides were obtained at a high purity (95%). They are
all readily soluble in distilled water or PBS.
Analysis of nucleolin by immunoblotting
Nucleolin was analyzed by immunoblotting using either
the monoclonal antibody (mAb) D3 against nucleolin
(kindly provided by Dr. J. S. Deng) [6], or rabbit polyclo-
nal antibodies directed against a synthetic peptide corre-
sponding to the first 26 (MVKLAKAGKNQGDPK
KMAPPPKEVEE) and the last 16 (GGGGDHKPQ
GKKTKFE) amino acid residues of human nucleolin as
described before [8]. Nucleophosmin was revealed using
rabbit monoclonal antibody EP1848Y (abcam). The
murine mAb D3 and rabbit antibodies were revealed
with horseradish peroxidase-conjugated sheep anti-
mouse and goat anti-rabbit immunoglobulin (Jackson
ImunoResearch), respectively. The reacting bands were
visualized with an enhanced chemiluminescence (ECL)
reagent and by exposure to autoradiography film (Amer-
sham Biosciences). In some experiments, the presence of
actin was monitored as a control with mAb anti-actin
A-4700 (Sigma).
Preparation of cytoplasmic and nuclear extracts
Cells washed in phosphate-buffered saline (PBS) were
lysed in buffer E (20 mM Tris-HCl, pH 7.6, 150 mM
NaCl, 5 mM MgCl2,5m Mb-mercaptoethanol, pro-
tease inhibitor cocktail (Sigma) and 0.5% Triton X-
100) and the nuclei were pelleted by centrifugation
(1000 g for 5 min). For the preparation of nuclear
extracts, the nuclear pellet was disrupted in buffer I
(20 mM Tris-HCl, pH 7.6, 50 mM KCl, 400 mM NaCl,
1m ME D T A ,5m Mb-mercaptoethanol, protease inhi-
bitor cocktail, 1% Triton X-100, and 20% glycerol).
Cytoplasmic and nuclear extracts were then centri-
fuged at 12,000 g for 10 min, and the supernatants
(nucleoplasm) were stored at -20°C. Aliquots of crude
cell extracts were diluted in 2 fold concentrated elec-
trophoresis sample buffer containing SDS, and pro-
cessed for immunoblotting analysis [9,10]. To monitor
the profile of proteins in crude cells extracts, gels were
stained with Brilliant Blue G-Colloidal Concentrate
from Sigma [37].
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Three days after passage of HeLa P4 cells (10 × 150 cm
2
flasks), subconfluent cell monolayers were washed twice
in PBS containing 1 mM EDTA before preparation of
cytoplasmic extracts using 10 × 200 μl buffer E. For the
gel filtration of surface nucleolin bound to the biotiny-
lated HB-19 (HB-19/Btn), HeLa cells were first incu-
bated with 5 μM of HB-19/Btn (45 min at room
temperature) before preparation of extracts. Cytoplasmic
extracts were diluted in PBS containing 1 mM EDTA
then centrifuged at 12,000 g for 10 min, and filtered
using Costar
® Spin-X
® centrifuge tubes filters (0.45 μm
membrane pores size). Gel-filtration chromatography
was carried out as previously described [50] on a GE
Pharmacia fast protein liquid chromatography (FPLC)
system. Briefly, a Superose™ 6c o l u m n( 1 . 6c m×5 0
cm) was equilibrated in buffer GF containing 20 mM
Tris/HCI, pH 7.6, 50 mM NaCl and 0.1% Triton X-100
at 0.5 ml/min. The column (bed volume 100 ml) was
calibrated using cell extracts supplemented with gel fil-
tration standard proteins from GE Healthcare Life
Sciences: thyroglobulin (669-kDa), catalase (232-kDa)
and BSA (67-kDa). Elution was in buffer GF with collec-
tion of 1-ml fractions/2 min, with a void volume (Vo)
and total elution volume (Vc) at 30 ml and 114 ml,
respectively. The void volume (Vo) was determined
from the elution profile of Blue Dextran 2000 and total
elution volume from the elution profile of Bromophenol
blue. The sample (1 ml) was loaded on the column, and
the eluate was monitored at 280 nm. Aliquots from
each fraction were assayed for DPP IV activity by the
cleavage of Gly-Pro-NH-Np (Sigma) in order to deter-
mine the peak of the 110-kDa DPP IV. The peaks of
thyroglobulin, catalase and BSA were determined by
polyacrylamide gel electrophoresis. The presence of
nucleolin in various fractions was revealed by
immunoblotting.
Purification of the cell surface expressed 500-KDa
complex containing surface nucleolin for
microsequencing of nucleolin-associated proteins
Twenty-four hours after passage, CEM cells (10
9 cells)
were washed extensively with PBS before incubation in
culture medium (RPMI, 10% FCS) at room temperature
for 30 min with 5 μM HB-19/Btn. After washing exten-
sively in PBS containing 1 mM EDTA (PBS/EDTA),
cytoplasmic extracts were prepared in lysis buffer E. The
complex formed between cell-surface-expressed nucleo-
lin and the HB-19/Btn was isolated by purification of
extracts using avidin-agarose (Simon-Pure Immobilized
Avidin from Pierce) in PBS/EDTA. After 2 h of incuba-
tion at 4°C, the samples were washed extensively with
PBS/EDTA. The purified proteins were denatured by
heating in the electrophoresis sample buffer containing
SDS and analyzed by SDS-PAGE (7.5%). The proteins
were transferred to a PVDF membrane before microse-
quencing the NH2-terminal ends (performed by the Pro-
tein-Sequencing Laboratory at Institut Pasteur, Paris).
Triggering the production of pro-inflammatory cytokines
by peripheral blood lymphocytes
Peripheral blood mononuclear cells (PBMC) from
healthy donors were prepared by Ficoll-Hypaque density
gradient centrifugation [45] and suspended in RPMI
1640 medium containing 1% (v/v) of human serum AB
(from Invitrogen). PBMC (10
6 cells/0.5 ml) in the
absence or presence of 10 μM of each of HB-19, N3,
N6, and N7, or 1 μg/ml of dexamethasone (Sigma) were
Table 1 HB-19 and related Nucant pseudopeptides
HB-19
Presents pentavalently the pseudo-tripeptide Lysψ(CH2N)-Pro-Arg coupled to the template: H2NLys-Lys-Lys-Gly-Pro-Lys-Glu-Lys-AhxCONH2.
Nucant 7: N7
Presents hexavalently the pseudo-tripeptide Lysψ(CH2N)-Pro-Arg coupled to a similar template as in HB-19: Ac-Lys-Ala-Lys-Pro-Gly-Lys-Ala-Lys-Pro-Gly-
Lys-Ala-Lys-Pro-Gly-CONH2.
Nucant 3: N3
Presents pentavalently the pseudo-tripeptide Lysψ(CH2N)-Pro-Arg coupled to the polypeptide template containing Aib (2-aminoisobutyric acid): Ac-
Lys-Aib-Gly-Lys-Aib-Gly-Lys-Aib-Gly-Lys-Aib-Gly-Lys-Aib-Gly-CONH2.
Nucant 6: N6
Presents hexavalently the pseudo-tripeptide Lysψ(CH2N)-Pro-Arg (a mixture in L and D configuration) coupled to the polypeptide template
containing Aib: Ac-Lys-Aib-Gly-Lys-Aib-Gly-Lys-Aib-Gly-Lys-Aib-Gly-Lys-Aib-Gly-Lys-Aib-Gly-CONH2.
Nucant 6L: N6L
Presents hexavalently the pseudo-tripeptide Lysψ(CH2N)-Pro-Arg (all bonds in L position) coupled to a polypeptide template as in N6.
HB-19 and related Nucant pseudopeptides present pentavalently or hexavalently the pseudo-tripeptide Lysψ(CH2N)-Pro-Arg; ψ(CH2N) stands for a reduced
peptide [9,16,43,44]. N6L has a similar template as N6 but the Lysψ-Pro units of the pseudo-tripeptide Lysψ(CH2N)-Pro-Arg moieties are all in L configuration,
while in N6 the Lysψ-Pro units are a mixture in L and D configuration [44,49]. The nucleolin blocking affinity of constructs that present hexavalently the pseudo-
tripeptide Lysψ(CH2N)-Pro-Arg (N6, N6L and N7) is 2-3 fold higher compared to the constructs that present pentavalently the same pseudo-tripeptide (HB-19 and
N3).
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8 particles/ml of Heat-killed Staphylo-
coccus aureus (HKSA; InvivoGen, San Diego, USA). The
cultures were incubated at 37°C in a 5% CO2 incubator,
and the level of TNF-a and IL-6 was monitored in the
culture supernatants by ELISA (R & D Systems) at 20
hours post-stimulation.
Inhibition of surface nucleolin function as a cell surface
receptor for HIV-1 entry into HeLa CD4+ cells
Surface nucleolin serves as a low affinity receptor impli-
cated in the binding and entry of HIV-1 particles into
permissive cells. Consequently, HB-19 treatment of cells
prevents HIV binding to cells and thus HIV entry and
infection [9,16]. Here HIV-1 LAI entry was monitored
in HeLa-CD4-LTR-LacZ cells containing the bacterial
lacZ gene under the control of HIV-1 LTR. Virus entry
and replication result in trans-activation of HIV-1 LTR
by the viral Tat protein, leading to the expression of b-
galactosidase. At 48 h post-infection, cell monolayers
are lysed in a phosphate buffer containing Nonidet P-40
(Sigma) (1%; v ⁄ v) and assayed for b-galactosidase activ-
ity by measuring optical density at 570 nm [45].
Analysis of the cell-surface-expressed nucleolin
Two days after seeding, subconfluent cells (about 5 ×
10
6 cells/75 cm
2 flask) were incubated (45 min, 20°C)
with 5 μM of HB-19/Btn. After washing extensively in
PBS containing 1 mM EDTA (PBS-EDTA), nucleus-free
cell extracts were prepared in lysis buffer E. The com-
plex formed between cell-surface expressed nucleolin
and HB-19/Btn was isolated by purification of the
extracts using NeutrAvidin agarose (100 μl; Pierce Bio-
technology) in PBS-EDTA. After 3 hours at 6°C, the avi-
din-agarose samples were washed extensively with PBS-
EDTA. The purified surface nucleolin was eluted in the
electrophoresis sample buffer containing SDS and ana-
lyzed by 10% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE). The presence of nucleolin was then
revealed by immunoblotting using mAb D3 as described
before [10,16]. All cells investigated in this study (MDA-
MB-231, MDA-MB-435, LNCaP, HeLa, SW480, SW620,
and T29) expressed the cell surface nucleolin assayed by
this procedure.
Immunofluorescence microscopy
Cells were plated 24 hours before the experiment in
eight-well glass slides (Lab-Tek Brand; Nalge Nunc
International, Naperville, IL). Cells were fixed with PFA/
Triton X-100 solution (PFA/Triton) for staining intra-
cellular biotinylated pseudopeptides (HB-19, N3, and
N7) and nucleolar nucleolin [6,16]. Polylysine (0.01%)
coated glass slides were used for adhesion of cells that
proliferate in suspension. S W 4 8 0a n dS W 6 2 0c e l l sp l a -
ted in glass slides were cultured in the absence (control)
or presence of 10 μM N6L for several days. Cells were
either photographed as such or washed with PBS before
fixation with PFA/Triton solution and processed for the
detection of nuclear nucleolin using mAb D3. The sec-
ondary antibodies were the following: FITC-conjugated
goat anti-mouse IgG (Sigma) and rabbit anti-biotin con-
centrate (IgG fraction; Enzo Dioagnostics, Inc., New
Y o r k ) .T h en u c l e iw e r es t a i n e dw i t h4 ’,6-diamidino-2-
phenylindole (DAPI). It should be noted that artifactual
results are observed when cells are fixed with methanol/
acetate (3/1) to reveal intracellular localization of HB-19
or Nucant pseudopeptides, as it is the case for intracel-
lular nucleolin [6,15].
Analysis of DNA fragmentation in response to Nucant
treatment
Extraction of nuclei in buffer I (prepared as above) from
viable cells results in the recovery of chromatin-free
nucleoplasm. However, during cell death when DNA
fragmentation occurs, the low molecular weight DNA
fragments are recovered in the nucleoplasm. Conse-
quently, supernatant of nuclear extracts from cells
undergoing programmed cell death contain low molecu-
lar weight DNA fragments, whereas the pellet of the
nuclear extracts contain the high molecular weight chro-
matin. By this experimental approach, DNA fragmenta-
tion could be analyzed without interference of the bulky
DNA [51]. For the preparation of the low molecular
weight DNA fragments, nucleoplasm was incubated
with 1 mg/ml RNase for 1 hour at 50°C, then 0.5 mg/ml
proteinase K for 1 hour at 50°C, followed by extraction
with phenol/chloroform/isoamyl alcohol (25:24:1) and
precipitation with ethanol. The DNA pellet was resus-
pended in electrophoresis buffer (10 mM Tris-HCI, pH
8.0, 1 mM EDTA) and analyzed by electrophoresis on
1.5% agarose gels containing 0.5 pg/ml ethydium
bromide.
mRNA expression monitored by reverse transcription-
polymerase chain reaction (RT-PCR)
SW620 cells were cultured in the absence or presence of
N7 before extraction for total RNA using RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions. RT
was carried out with oligo(dT) and 2-4 μgo ft o t a lR N A
using Superscript II Reverse Transcriptase (Invitrogen).
PCR was performed in a RoboCycler 96 (Stratagene, La
Jolla, CA, USA) with specific primers for human nucleolin
(referred to as NCL) 5’-TTGAATTCATCATGGTGAAG
CTCGCGAAGGC-3’ and 5’-TAGGGCCCAGGCTCTT
CCTCCTC-3’ (835 bp); glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) 5’-TGAAGG-TCGGAGTCAACG-
GATTTGGT-3’ and 5’-CATGTGGGCCATGAGGTCCA-
CCAC-3’ (983 bp); nucleophosmin (NPM or B23) 5’-
TGGTTCTCTTCCCAAAGTGG-3’ and 5’-TAAAACC
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nase-2 (MMP-2) 5’-GTGCTGAAGGACACACTAAA-
GAAGA-3’ and 5’-TTGCCATCCTTCTCAAAGT
TGTAGG-3’ (580 bp); matrix metalloproteinase-9 (MMP-
9) 5’-CACTGTCCACCCC TCAGAGC-3’ and 5’-GCC
ACTTGTCGGCGATAAGG-3’ (243 bp); tissue inhibitor
of metalloproteinase 1 (TIMP-1) 5’-ATCCTGT
TGTTGCTGTGGCTGATAG-3’ and 5’-TGCTGGGT
GGTAACTCTTTATTTCA-3’ (667 bp); tissue inhibitor of
metalloproteinase 2 (TIMP-2) 5’-AAACGACATT-
TATGGCAACCCTATC-3’ and 5’-ACAGGAGCCGT-
CACTTCTCTTGATG-3’ (405 bp). PCR amplification
conditions were: 95°C for 5 min, 30 cycles at 95°C for 30
sec, 60°C for 30 sec and 72°C for 45 sec, and 72°C for 5
min (for NCL and GAPDH), 95°C for 5 min, 30 cycles at
95°C for 30 sec, 53°C for 30 sec and 72°C for 30 sec, and
72°C for 5 min (for NPM); 95°C for 5 min, 35 cycles at 95°
C for 45 sec, 56°C for 45 sec and 72°C for 45 sec, and 72°C
for 5 min (for MMP2 and MMP9); 95°C for 5 min, 30
cycles at 95°C for 45 sec, 59°C for 1 min and 72°C for 1
min 30 sec, and 72°C for 5 min (for TIMP1 and TIMP2).
Statistical analysis
The significance of variability between the results of
each group and its corresponding control was deter-
mined by unpaired t-test and Mann-Witney Anova. All
results are expressed as mean ± standard errors of the
means from at least two independent experiments.
Results and Discussion
The cell-surface expressed nucleolin exists in a complex
of high molecular weight
The elution profile of nucleolin was investigated by gel
filtration of Triton-X100 soluble cell extracts of cyto-
plasmic and plasma membrane proteins. Immunoblot-
ting aliquots from various fractions then revealed the
presence of three nucleolin peaks located within frac-
tions 3-8, 10-17 and 19-21, which correspond to the
elution profile of proteins of apparent molecular weights
of 500-, 200-, and 100-kDa, respectively (Figure 1A).
The 100-kDa nucleolin peak is in accord with its mole-
cular mass after SDS-PAGE analysis, and should corre-
spond to the monomeric form of nucleolin. On the
other hand, the higher molecular weight peaks of
nucleolin could correspond to nucleolin multimers or
nucleolin complexed with other proteins.
In order to differentiate between nucleolin expressed
on the cell surface from that found in the cytoplasm, we
carried out a similar gel filtration experiment but using
extracts from cells that were preincubated at room tem-
perature with biotinylated HB-19 (HB-19/Btn). At
reduced temperatures, HB-19 binds surface nucleolin
and forms a stable complex but it is not internalized,
thus allow the differentiation between surface and
cytoplasmic nucleolin. After gel filtration, nucleolin was
recovered in two main peaks located in fractions 3-9 and
19-23 corresponding to apparent molecular weight of
500- and 100-kDa, respectively, whereas the peak at the
molecular weight of 200-kDa was greatly reduced (Figure
1B). For the recovery of nucleolin complexed to HB-19/
Btn, fractions 1-7 and 17-24 were purified by affinity
chromatography using avidin-agarose Figure 1C and 1D).
The results indicate that the peak of nucleolin eluting at
an apparent molecular weight of 500-kDa represents sur-
face nucleolin, whereas the 100-kDa peak corresponds to
nucleolin present in the cytosol. The marked reduction
of the 200-kDa nucleolin peak might reflect the shift of
this form of nucleolin towards the cell surface during the
incubation period of cells with HB-19/Btn. Taken
together, these results indicate that the existence of sur-
face nucleolin in a high molecular weight complex is
independent of ligand binding to surface nucleolin.
Identification of proteins associated with the surface
expressed nucleolin in the 500-kDa complex
The 500-kDa complex containing surface nucleolin was
purified from the cell surface by the capacity of HB-19/
Figure 1 Gel filtration of HeLa cell extract containing
cytoplasmic and plasma membrane proteins. A. The preparation
of Triton-X100 soluble cell extract was analyzed by gel filtration
using a superose-6 column. One ml fractions (numbered from 1 to
25) were collected after the elution of the void volume (Vo), and
the presence of nucleolin was monitored by immunoblotting using
rabbit polyclonal antibodies against the NH2-terminal peptide of
nucleolin. The numbers 232, 110 and 67 on the top indicate the
position of protein markers of molecular weight 669-, 232-, 110-,
and 67-kDa. NCL on the right shows the main nucleolin band at
position 100-kDa. The other low molecular weight bands represent
the cleaved products of nucleolin. B. HeLa cells were first incubated
with 5 μM of HB-19/Btn at room temperature before preparation of
cell extracts. Gel filtration was carried out as in section 1A, but only
one every other sample was analyzed by immunoblotting. C/D. The
peak of nucleolin eluting at an apparent molecular weight of 500-
kDa is complexed with HB-19/Btn. Fractions 1-7 and 17-24 from the
gel filtration experiment described in section B were purified by
affinity chromatography using Avidin agarose and analyzed by
immunoblotting. On the right of the different gels is the position of
the molecular weight markers. All experimental procedures were as
described in Methods.
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Page 6 of 22Btn to bind specifically surface nucleolin [9,16,52]. This
500-kDa complex is highly stable but it becomes disso-
ciated in the presence of the ionic detergent SDS. Con-
sistent with our previous results, we first confirmed that
nucleolin is the only HB-19 binding protein band by
ligand blotting using HB-19/Btn [9,16,52]. Secondly, by
staining of the SDS-PAGE gel we revealed the presence
of several other protein bands, which were processed for
NH2-terminal microsequencing (Table 2 Table 3; Addi-
tional file 2, Figure S2). Such surface nucleolin asso-
ciated proteins were identified as two Wnt related
proteins, the 80-kDa subunit of the Ku autoantigen, the
signal recognition particle subunits SRP72 and SRP68, a
protein described in the literature as p32 or the hyaluro-
n a nb i n d i n gp r o t e i n1( H A B P 1 )o ra st h er e c e p t o rf o r
complement component C1q (gC1q-R), and ribosomal
proteins S4 and S6. Like surface nucleolin, gC1q-R is
glycosylated and lacks GPI anchor or a transmembrane
segment. The mature gC1q-R protein localized at the
cell surface lacks its first 73 amino acid residues [53].
Consistent with this, the NH2-terminal sequence that
we obtained for gC1q-R purified with the cell surface
nucleolin starts at amino acid residue 74 (Table 2). The
most abundant location of p32/gC1q-R is in the mito-
chondria where it is shown to be a critical regulator of
tumor metabolism via maintenance of oxidative phos-
phorylation [54]. However, the effect of surface gC1q-R
on its mitochondrial counterpart is not yet elucidated.
Cell surface expressed gC1q-R can serve as a receptor
for diverse proinflammatory ligands, and as a binding
protein for a number of functional antigens of viral and
bacterial origin. Particularly, Staphylococcus aureus via
i t sp r o t e i nAu s e sg C 1 q - Ra sac e l l u l a rp r o t e i nf o r
attachment and/or entry into host cells [55]. Previously,
Table 2 Identification of nucleolin associated proteins in the 500-kDa complex
Protein Band (MW) Obtained Sequence
1/Medline Sequence
2
Band 5 (90-kDa) MHRPFXX
1
1-MHRNFRK
2 = Wnt related protein A
3
Band 6 (85-kDa) MRPMTQIIVQD
1
1-MRPMTFIVGLK
2 = Wnt related protein B
4
Band 7 (80-kDa) VRSGNKAAVVLXMDVXFTMS
1
1-MVRSGNKAAVVLCMDVGFTMS = Ku80
5
Band 8 (72-kDa) ASGGSGGVXVPA
1
1-MASGGSGGVSVPA
2 = SRP72
6
Band 9 (68-kDa) AAEKQVPGGXXGGGS
1
1-MAAEKQVPGGGGGGGS
2 = SRP68
6
Band 11 (32-kDa) LHTDGDKAFVDFLSD
1
74-LHTDGDKAFVDFLSD
2 = p32/p33/HABP1/gC1q-R
7
Bands 12 (25-kDa): ARGPKKHLK
1
1-MARGPKKHLK
2 =S 4
8
KLNISFPAL
1
1-MKLNISFPAL
2 =S 6
8
By the capacity of the HB-19/Btn to bind surface nucleolin, the 500-kDa complex was recovered from the cell surface and purified using avidin-agarose. After
analysis by SDS-PAGE, several protein bands of 90-, 85-, 80-, 72-, 68-, 32, and 25-kDa were processed for NH2-terminal microsequencing (Methods; Additioal file 2,
Figure 2S). These protein bands were identified as Wnt related proteins, Ku80, SRP68, SRP72, p32/p33/HABP1/gC1q-R, and ribosomal proteins S4 and S6.
1 The obtained NH2-terminal sequence.
2 The NH2-terminal sequence in the Medline.
3 The obtained MHRPFXX sequence shares homology to the N-terminal sequence of human Wnt-7b (MHRNFR) [87].
4 The obtained MRPMTQIIVQD sequence is homologous in its first 5 amino acid residues with the N-terminal sequence (MRPMTFIVGLK) of Wnt-1 of the Mexican
axolotls Ambystoma mexicanum [88]. Consequently, the isolated protein appears to correspond to a human Wnt-related protein that remains to be described.
5 The 80-kDa subunit of the Ku autoantigen [89]
6 The 68- and 72-kDa subunit of the signal recognition particle [60].
7 Referred in the literature as the protein p32 associated with the splicing factor SF2, the hyaluronan binding protein 1 (HABP1) and the receptor for complement
component C1q (gC1q-R)[90].
8 Ribosomal proteins S4 and S6 [91].
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Page 7 of 22the urokinase receptor and caseine kinase have been
reported to colocalize with surface nucleolin [56]. How-
ever, we did not identify them among the other nucleo-
lin-associated proteins recovered from the surface of
cells (Table 2). This latter could be the consequence of
our failure to microsequence some of the protein bands
because of poor recovery from the PVDF membrane or
blockade of their NH2-terminal end (see the Additional
file 2, Figure S2). On the other hand, we cannot exclude
the possibility that nucleolin in the 200-kDa peak is
complexed with urokinase, which like HB-19 binds the
RGG domain of nucleolin [20].
Interestingly, most of surface-nucleolin associated pro-
teins are implicated in cell signaling, tumor cell adhe-
sion, migration, invasion, cell death, and inflammation
(Table 3). In addition, Ku and nucleolin are important
autoantigens in patients with systemic lupus erythema-
tosus and other systemic autoimmune disorders [57,58],
thus suggesting the potential implication of the 500-kDa
complex in autoimmune diseases. The mechanism by
w h i c hK ui st r a n s l o c a t e dt ot h ec e l ls u r f a c ei sn o t
known. However, it is of interest to note that in the
cytoplasm both Ku and nucleolin are packaged within
small vesicles, and are translocated to the cell surface by
a mechanism independent of the conventional endoplas-
mic reticulum/Golgi secretory pathway [6,59]. In view of
the observation that SRP68 and SRP72 are associated
with the high molecular weight nucleolin complex
(Table 2), and the implication of SRP in the cotransla-
tional delivery of nascent secretory and membrane pro-
teins [60,61], it is tempting to speculate that SRP could
coordinate active translocation of Ku and nucleolin
towards the plasma membrane.
None of the isolated proteins in the 500-kDa com-
plex including nucleolin possess a hydrophobic trans-
membrane domain to account for anchorage in the
plasma membrane. In spite of this, the 500-kDa com-
plex is tightly associated with the plasma membrane
because extensive washing of cells with high concen-
trations of EDTA, EGTA, or NaCl have no effect. On
the other hand, the 500-kDa complex is readily recov-
ered by solubilization of the plasma membrane with
non-ionic detergents, Triton X-100 or NP-40, thus
indicating that its association with the cell surface is
through non-covalent interactions. The surface nucleo-
lin in the 500-kDa complex should be associated,
directly or indirectly, to an integral membrane protein
partner that holds this complex to coordinate cluster-
ing of surface nucleolin along with active endocytosis
of various nucleolin-binding ligands via lipid rafts
[10,17,19]. A potential candidate for a transmembrane
protein partner of the 500-kDa complex is the low-
density lipoprotein (LDL) receptor related protein
(LRP1), which is a large scavenger receptor mediating
endocytosis of various biological components and is
largely implicated in cytoskeleton organization
[7,62,63]. The link between the 500-kDa complex and
LRP1 could be apoplipoprotein E-enriched LDL that in
addition to LRP1 binds also surface expressed nucleo-
lin. Accordingly, anti-nucleolin antibody has the capa-
city to inhibit significantly the binding of LDL to the
cell surface [64]. Interestingly, active internalization of
Table 3 Characteristics of proteins associated with the cell surface expressed nucleolin
Wnt related protein A and B. Protein A shares homology with human Wnt-7b [87], while protein B shares homology with Wnt-1 of the Mexican
axolotl Ambystoma mexicanum [88]. The Wnt proteins are a family of secretory glycoproteins mostly associated with cell membranes and the
extracellular matrix. They are implicated in proliferation and differentiation of both normal and malignant cells. Many members of the WNT gene
family, including WNT-7, are up-regulated in bladder and breast carcinoma and as well as in chronic lymphocytic leukemia, suggesting involvement
of Wnt signaling pathways in tumorigenesis [92-94].
80-kDa subunit of Ku. The Ku autoantigen is a heterodimeric protein made up of 70- and 80-kDa subunits. Besides its central importance to DNA
repair, Ku has a key role in a number of other fundamental cellular processes such as telomere maintenance, transcription and cell death [89]. The
cell surface expressed Ku80 is detected in a variety of tumor cells, including leukemia and solid tumor cells [95]. Surface Ku contributes to adhesion
and invasion of tumor cells thus potentiating tumor metastasis [59].
SRP68 and SRP72. These are the 68- and 72-kDa subunit in the signal recognition particle, a ribonucleoprotein complex composed of 7S RNA and
6 proteins of 9-, 14-, 19-, 54-, 68-, 72-kDa. SRP comprise the major cellular machinery that mediates the cotranslational targeting of proteins to
cellular membranes [60,61]. SRP68 and SRP72 are functionally linked. Experimental evidence has demonstrated that SRP68 binds SRP72 and forms a
highly stable heterodimer [96].
32-kDa protein referred to as p32/p33, HABP1, or gC1q-R. A multifunctional and muticompartmental cellular protein that was originally isolated
based on its copurifiation with the nuclear splicing factor SF2 (p32/p33). It has also been described on the cell surface as the hyaluronan binding
protein 1 (HABP1) and the receptor for complement component C1q (gC1q-R) [97]. Hyaluronan is a glycosaminoglycan that with its surface
receptors regulate tumor cell adhesion, migration and invasion [98]. Preferentially over expressed in adenocarcinoma cells, gC1q-R is a molecular
target in tumor cells and tumor stroma [90,99]. In addition to cancer, gC1q-R is considered to play an important role in bacterial infections and
inflammation [54,55].
Ribosomal proteins S4 and S6. S4 and S6 are respectively components of the 40S and 60S ribosomal subunits, which generate ribosomal 80S
subunit implicated in the cellular process of translation. Ribosomal proteins with nucleolin are also implicated in the processing and assembly of
pre-ribosomal particles in the nucleolus. Like HB-19, several ribosomal proteins bind nucleolin via its RGG domain [9,91]. The role, if any, of the
surface expressed S4 and S6 remains to be investigated. It is worthwhile to note that several ribosomal protein genes have been reported to act as
cancer genes in zebrafish [100].
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Page 8 of 22specific surface nucleolin ligands (midkine, pleiotro-
phin, lactoferrin, HB-19) is dependent on the expres-
sion of LRP-1 [7,15,17-19,21,65]. Moreover, the
expression of surface nucleolin appears to be depen-
dent on the expression of LRP1. For example, in Chi-
nese hamster ovary CHO LRP1-null cells, although
nucleolin is present abundantly in the nucleus and in
the cytoplasm, it remains undetectable at the cell sur-
face (Additional file 3, Figure S3). Consequently, in the
absence of surface nucleolin in such LRP1-null cells,
ligands of nucleolin become internalized by a receptor-
independent passive process (Additional file 3, Figure
S4). These reports and observations suggest that LRP1
might be one of the potential transmembrane anchored
partners that allow surface expression of nucleolin in
the 500-kDa complex. The mechanism by which LRP1
expression could coordinate the expression of nucleo-
lin at the cell surface remains to be elucidated.
HB-19 and related Nucant pseudopeptides exert distinct
inhibitory effects on different types of tumor cells in
culture
HB-19 presents pentavalently the pseudo-tripeptide
Lysψ(CH2N)-Pro-Arg coupled to a peptide template. In
order to improve the biological activity of HB-19, several
new constructs named Nucant (for nucleolin antagonist)
were generated (Methods). These constructs present
either pentavalently (N3) or hexavalently (N6, N6L and
N7) a similar pseudo-tripeptide Lysψ(CH2N)-Pro-Arg as
HB-19 (Table 1; Additional file 1, Figure S1). The
nucleolin-antagonist effect of HB-19 and Nucant con-
structs were assayed conveniently by their capacity to
block HIV-1 entry into permissive cells [10,16,45].
Accordingly, we show that HB-19 and related Nucant
constructs inhibit HIV-1 entry in a dose dependent
manner (Figure 2A and 2C). The inhibitory activity of
N3 is similar to that of HB-19. On the other hand, the
inhibitory activity of N6/N7 and N6L is at least 2- and
4-fold more active, respectively, compared to the penta-
valent constructs N3 and HB-19. After binding surface
nucleolin, Nucant constructs like HB-19 [37] are inter-
nalized by an active process and accumulate in the cyto-
plasm without entering the cell nucleus. An example is
presented in the Additional file 4, Figure S5 showing the
cytoplasmic entry of the biotinylated HB-19, N3, and
N7 in MDA-MB 231.
Finally, treatment of cells with HB-19 and Nucant
constructs results in a drastic down regulation of sur-
face/cytoplasmic nucleolin without affecting nuclear
nucleolin (Figure 2B). Interestingly, the reduction of sur-
face/cytoplasmic nucleolin is greater in cells treated with
N6 and N7 compared to cells treated with HB-19 and
N3. In fact, the level of surface/cytoplasmic nucleolin is
almost completely abolished in cells treated with either
N6 or N7. This is due to a selective reduction of sur-
face/cytoplasmic nucleolin, since the profile of cytoplas-
mic proteins assayed by Brilliant Blue G-Colloidal
Concentrate staining is comparable in the untreated
control and HB-19 or Nucant treated cells (Figure 2B).
Consistent with its higher activity as an antagonist of
surface nucleolin (Figure 2C), N6L treatment causes a
drastic down regulation of surface but not nuclear
nucleolin in a dose dependent manner (Figure 2D). At 1
μM of N6L surface nucleolin level is reduced by more
than 80%, whereas at 2 μM concentration surface
nucleolin is no longer detectable. Taken together, these
results indicate that selective reduction of surface/cyto-
plasmic nucleolin occurs independently of nuclear
nucleolin, which further illustrates that HB-19 and
Nucant pseudopeptides exert their inhibitory effects
without toxicity. We have recently reported that in spite
of reduction of surface/cytoplasmic nucleolin protein,
nucleolin mRNA is continuously induced but it is not
translated [15]. The molecular mechanism of such a
specific translational block on nucleolin mRNA in HB-
19 and Nucant treated cells remains to be investigated.
However, it is tempting to speculate that nucleolin
mRNA might require the nucleolin protein for its trans-
lation as it is the case for metalloproteinase-9 (MMP-9)
and bcl2 oncogene mRNA [4,5].
During our initial studies to test the inhibitory activ-
ity of HB-19 and related Nucant pseudopeptides on
various tumor cell lines, we noticed that they exert dis-
tinct inhibitory mechanisms depending on the malig-
nant tumor cell type. Indeed, in epithelial tumor cells
they induce reversion of the malignant phenotype
while in leukemia cells they trigger a programmed cell
death. Table 4 gives a summary of the inhibitory activ-
ity of hexavalent Nucant consructs N6/N7 compared
to N6L on various epithelial tumor cell lines and on
leukemia cells. Such Nucant constructs inhibited mark-
edly the growth of all types of tumor cell lines after 3
days of treatment, but more strikingly they selectively
induced cell death only in leukemia cells after 24
hours of treatment. In the group of the epithelial cell
lines, we noticed that Nucant treatment could affect
adhesion of cells (MDA-MB 435, MDA-MB 231,
LNCaP, and HeLa cells), restore contact inhibiton
(TIII, MDA-MB 435, and MDA-MB 231 cells), inhibe
spreading (SW480 and SW620 cells) and migration
(MDA-MB 435, MD1-MB 231) of tumor cells. Conse-
quently, we used these different cell lines to demon-
strate the distinct inhibitory action of HB-19 and
related Nucant pseudopeptides.
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Page 9 of 22Figure 2 HB-19 and related Nucant pseudopeptides antagonize surface nucleolin and trigger its down regulation.A .M u l t i v a l e n t
pseudopeptides block the biological function of surface nucleolin for HIV entry. HeLa CD4+ cells in the absence (histogram C) or presence of
0.1, 0.2, 0.4 and 0.8 μM of HB-19, N3, N6, and N7 were assayed for HIV-1 entry into cells. At 48 h post-infection, the b-galactosidase activity was
measured in cell extracts directly to monitor HIV entry (Methods). The abscissa gives % Activity of surface nucleolin calculated from the optical
density measurements at 570 nm. The mean standard deviation (± SD) of triplicate samples is shown. B. Down regulation of surface nucleolin by
multivalent pseudopeptides. Two days after passaging MDA-MB 231 cells were untreated (lanes Control) or treated with 10 μM of HB-19, N3, N6,
and N7 for 16 hours. Cytoplasmic (containing cytoplasmic as well as surface nucleolin) and nuclear extracts were analyzed by immunoblotting
using mAb D3 as described (Methods)(panels Surface/cytoplasmic NCL, Nuclear NCL). The corresponding cytoplasmic extracts from section B
were stained with Brilliant Blue G-Colloidal Concentrate staining (panel Stained Cytoplasmic extract). C. Hexavalent N6L pseudopeptide blocks
the biological function of surface nucleolin for HIV entry in a dose dependent manner. HeLa CD4+ cells in the absence (histogram C) or
presence of 0.05, 0.1, 0.2, 0.4 and 0.8 μM of N6L were assayed for HIV-1 entry into cells as in section A. D. Down regulation of surface nucleolin
by N6L in HeLa CD4+ cells in a dose dependent manner. HeLa cells in the absence (histogram C) or presence of 1, 2, 5, and 10 μM of N6L were
cultured for 7 hours before preparation of cell extracts and immunoblotting as in section B. The intensity of nucleolin protein bands was
quantified by using the NIH image software. The values for the statistical significance in section A and C are the following: p is < 0.1 for HB-19
and N3 at 0.1 μM, whereas p is < 0.001 at higher concentration of HB-19 and N3; p is < 0.001 for N6, N7, and N6L at the various concentrations
used for the assay.
Krust et al. BMC Cancer 2011, 11:333
http://www.biomedcentral.com/1471-2407/11/333
Page 10 of 22The inhibitory action of HB-19 and related Nucant
pseudopeptides on the production of pro-inflammatory
cytokines by human blood lymphocytes in response to
stimulation by heat inactivated Staphylococcus aureus
Surface nucleolin does not dissociate from the other
proteins in the 500-kDa complex in the presence of
non-ionic detergents thus indicating that these proteins
are bound together. This and the capacity of HB-19 to
bind surface nucleolin without dissociating the 500-kDa
complex suggest that the binding of HB-19 to surface
nucleolin could change the organization of the 500-kDa
complex, and thus interfere with the proper functioning
of nucleolin and the nucleolin associated proteins. In
order to test this hypothesis, we investigated the capa-
city of the nucleolin antagonist pseudopeptides to inter-
fere with one of the functio n so fg C 1 q - Ra sac e l l u l a r
receptor of Staphylococcus aureus [55]. Human periph-
eral blood lymphocytes in the absence presence of
nucleolin antagonist pseudopeptides were stimulated by
Heat-killed Staphylococcus aureus (HKSA) and the pro-
duction of proinflammatory cytokines TNF-a and IL-6
was monitored in culture supernatants at 20 hours post-
stimulation (Figure 3). As a control for the inhibition of
the inflammatory response, lymphocytes were treated
with dexamethasone, which is a glucocorticoid drug
with a known potent anti-inflammatory and immuno-
suppressant activity. We show that nucleolin antagonist
pseudopeptides inhibit production of TNF-a and IL-6 in
HKSA-stimulated primary lymphocytes by 55-66% and
41-64%, respectively, while dexamethasone inhibits by
61 and 62%, respectively (Figure 3). A similar inhibitory
effect is observed when cells are first treated with HB-
19 and Nucant pseudopeptides at 20°C, washed to
remove unbound pseudopeptides before addition of
HKSA at 37°C (data not shown). Therefore, by targeting
surface nucleolin it is possible to interfere indirectly
with the functioning of the other proteins associated
with nucleolin in the 500-kDa complex, which is logical
when considering the various inhibitory mechanisms
triggered by HB-19 and Nucant pseudopeptides. Our
results suggest that the inhibitory action of these pseu-
dopeptides is mediated by their capacity to interact with
surface expressed nucleolin rather than with HKSA.
Nevertheless, we cannot exclude the possibility that the
interaction of these pseudopeptides with nucleolin could
trigger some downstream signaling event that inhibits
production of TNF-a and IL-6.
The inhibitory activity on the production of inflam-
matory cytokines provide an important contribution to
the overall anti-tumorigenic action of HB-19 and
related Nucant pseudopeptides, since inflammation
could constitute a risk factor for a variety of epithelial
cancers by generation of free radicals, stimulation of
cytokines, chemokines, and growth and angiogenic fac-
tors [66]. It is of interest to note that surface nucleolin
is an eukaryotic receptor for the adhesin intimin-
gamma of enterohemorrhagic Escherichia coli [11,67].
In view of this and the capacity of nucleolin antagonist
pseudopeptides to block functioning of gC1q-R, we
suggest that HB-19 and related Nucant pseudopeptides
could also provide efficient inhibitors of pathogenic
bacteria.
Table 4 Inhibitory activity of hexavalent Nucant pseudopeptides N6, N7, and N6L in tumor cell lines of different
origins
Cell line Tumor cell origin % Growth inhibition % Cell death
After 3 days
(N6/N7 - N6L)
After 24 hours
(N6/N7 - N6L)
MDA-MB 231 Hu breast cancer 92 - 95% < 5%
MDA-MB 435 Hu breast cancer 58 - 66% < 5%
LNCaP Hu prostate cancer 88 - 90% < 5%
HeLa Hu cervical cancer 46 - 60% < 5%
SW480 Hu colon carcinoma 25 - 35% < 5%
SW620 Hu colon carcinoma 45 - 55% < 5%
TIII Mu melanoma cells 55 - 83% < 5%
HuT 78 Hu cutaneous T cell leukemia 62 - 83% 44 - 55%
Jurkat Hu T-cell leukemia 80 - 85% 45 - 60%
RAJI Hu Burkitt lymphoma 75 - 95% 42 - 71%
HL60 Hu acute promyelocytic leukemia 65 - 80% 35 - 48%
T29 Mu T-cell lymphoma 85 - 95% 45 - 65%
Epithelial (MDA-MB 231, MDA-MB 435, LNCaP, HeLa, SW480, SW620, TIII) and leukemia (HuT 78, Jurkat, RAJI, HL60, and T29) cell lines were cultured in the
absence or presence of N6 or N7 (20 μM) or N6L (10 μM) to test their inhibitory activity on cell growth (by measuring viable cell number after 3 days of culture)
and cell death (by monitoring the trypan blue uptake after 24 hours of treatment of subconfluent epithelial and freshly passaged leukemia cells). The number of
viable cells in untreated control samples was used to calculate the % inhibition of cell growth and % cell death. Hu and Mu stand for human and murine origin,
respectively. The mean percentage values of at least 2 independent experiments are presented.
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spreading of human carcinoma cells
At concentrations that Nucant constructs do not affect
the viability of several epithelial carcinoma cells, they
inhibit attachment of cells to the plastic culture flask. A
typical experiment is presented in Figure 4A showing
dose dependent inhibitory effect of N6 on the attach-
ment of human breast (MDA-MB-231 and MDA-MB-
435) and prostate (LNCaP) carcinoma cells. At 10 μM
of N6, the degree of adhesion inhibition in MDA-MB-
231, MDA-MB-435 and LNCaP cells is 58, 41, and 66%,
respectively. As a consequence of cell adhesion, cultur-
ing of cells with Nucant results in a dose dependent sig-
nificant inhibition of cell growth, and moreover could
restore contact inhibition (Figure 4C; Additional file 5,
Figure S6). Similarly, Inhibition of cell proliferation of
melanoma TIII cells by Nucant pseudopeptides is highly
correlated with their capacity to inhibit cell adhesion.
Consistent with the capacity to block the biological
function of surface nucleolin at lower concentrations
(Figure 2), the inhibitory effects were more pronounced
with N6L compared to N6 (Table 5). It should be noted
that HB-19 and related Nucant pseudopeptides are
devoid of any significant cytotoxicity against such
Figure 3 HB-19 and related Nucant pseudopeptides inhibit the
production of TNF-a and IL-6 by peripheral blood
lymphocytes. The production of pro-inflammatory cytokines in
PBMC cultures stimulated with HKSA was carried out in triplicate in
the absence (Control) or presence of 10 μM of each of HB-19, N3,
N6, N7, N6L, or 1 μg/ml of dexamethasone (Dex.)(Methods). The
level of TNF-a (section A) and IL-6 (section B) was monitored in
culture supernatants by ELISA. The data presents the mean ± SD of
triplicate samples. The degree of inhibition is indicated at the top of
each histogram. Statistical significance: **p < 0.01, ***p < 0.001.
Figure 4 The inhibitory effect of Nucant on cell adhesion
occurs without any apparent cytotoxicity. A. Inhibition of Cell
adhesion by N6. MDA-MB 231, MDA-MB-435 and LNCaP (1 × 10
6)
cells were passaged in 25 cm
3 flasks in the absence (lanes 0 μM for
control) or presence of 5, 10, and 20 μM of N6. After 16 hours of
culture, adherent cells were trypsinized and the number of cells in
each flask was monitored in the presence of trypan blue. B. Cell
multiplication is not affected in Nucant cultured cells. Cells were
seeded at 2 × 10
5 cells in 25 cm
3 flasks. When cells reached
subconfluency (after 48 hours), they were further cultured for 24
hours in the presence of different concentrations of N6 before
counting. C. The effect of Nucant treatment on cell proliferation.
Seven hours after seeding (1 × 10
5 cells in 25 cm
3 flasks), cells were
cultured in the presence of different concentrations of N6 and
counted after four days. The ordinates give the mean ± SD of
triplicate samples. Statistical significance: **p < 0.01, ***p < 0.001.
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Page 12 of 22epithelial tumor cell lines in culture. For an example,
the viable cell number is not affected when subconfluent
MDA-MB-231, MDA-MB-435 or LNCaP cell mono-
layers are cultured for 24 hours in the presence of dif-
ferent concentrations of N6 (Figure 4B). Our results
suggest that inhibition of cell adhesion is one of the
inhibitory mechanisms of action of HB-19 and Nucant
pseudopeptides leading to inhibition of cell proliferation
of epithelial-like tumor cells. It is of interest to note that
adhesion of tumor cells on the vasculature of endothe-
lium is a critical and a decisive step in tumor cell inva-
sion and metastasis. In this respect, Figure S7 in the
Additional file 5 presents a typical experiment showing
that Nucant treatment could down regulate motility of
tumor cells as analyzed by a wound healing scratch
assay [68]. Finally, adhesion of tumor cells to platelets
also leads to the formation of micro-thrombin, which
facilitates the metastasis process by allowing tumor cells
to arrest in blood stream and to adhere to vascular wall
[69,70].
The inhibitory effect of Nucant on the spreading of
human colon carcinoma cells is associated with down
regulation of MMP-9 and nucleolin transcripts
In these experiments we used SW480 and SW620 cells
that are established from a primary and a metastatic
colon carcinoma, respectively. These cells were studied
in this section because of a particular effect of pseudo-
peptides on the spreading of such tumor cells. Both cell
types could spread on the plastic but piled up in cell
culture forming clusters of several layers of cells.
Treatment of both SW480 and SW620 cells with N6L
and N7, that present hexavalently the pseudo-tripeptide
Lysψ(CH2N)-Pro-Arg, resulted in growth inhibition of
cells (Table 6). In addition, Nucant treatment resulted
in a marked inhibitory effect on spreading SW480 and
SW620 cells which formed isolated circular colonies
(Figure 5). The inhibitory effect of Nucants on cell pro-
liferation and spreading was consistently observed in
SW480 and SW620 cells. In general, SW620 cells
appeared to be more sensitive to the inhibitory effect of
Nucant than SW480. This difference might be due to
the fact that SW480 cells form larger clusters of cells
that proliferate in several thick layers compared to the
metastatic SW620 cells.
The effect of Nucant on the expression of specific
mRNAs was investigated in SW620 cells by RT-PCR
Table 5 Inhibitory activity of N3, N6, and N6L on
melanoma TIII cell adhesion and proliferation
Nucant % Inhibition of cell
Adhesion Proliferation
N3: 5 μM No effect No effect
N3: 10 μM 15% 10%
N3: 20 μM 24% 36%
N6: 2.5 μM 15% 12%
N6: 5 μM 26% 20%
N6: 10 μM 38% 32%
N6: 20 μM 55% 45%
N6L: 2.5 μM 39% 45%
N6L: 5 μM 49% 56%
N6L: 10 μM 65% 80%
N6L: 20 μM 72% 85%
Epithelial melanoma TIII cells were cultured in the absence or presence of
different concentrations of N3, N6, and N6L to monitor inhibition of cell
adhesion (after 5 hours of cell seeding) and cell proliferation (after 3 days of
culture). The number of viable cells in untreated control samples was used to
calculate % inhibition of cell adhesion and proliferation. The mean percentage
values of at least 2 independent experiments are presented.
Table 6 Nucant pseudopeptides inhibit proliferation of
human colon carcinoma cells
Cells Nucant Number of cells % inhibition
SW480 None: Control 1,500,000 -
N7: 10 μM 1,200,000 20%
N7: 20 μM 900,000 40%
N6L: 10 μM 800,000 47%
SW620 None: Control 1,800,000 -
N7: 10 μM 1,000,000 44%
N7: 20 μM 700,000 61%
N6L: 10 μM 450,000 75%
Cells seeded in 6-well plates at 20,000 cells/ml in 2 ml culture medium were
cultured in the absence (Control) or presence of N7 and N6L. Seven days after
seeding, cells were trypsinized and counted. Nucant pseudopeptides were
added only once 5 hours after seeding of cells. Consistently, N6L manifests at
least 2-fold higher inhibitory activity compared to N7.
Figure 5 N6L treatment results in a marked phenotypic change
in human colon carcinoma cells giving typical circular colonies
instead of spreading and growing in several layers. SW420 (in
section A; phase contrast images) and SW620 (in section B,
immunofluorescence images) cells were cultured in the presence of
10 μM N6L for 3 days before analysis (Methods). The
immunofluorescence images show nucleolin in the nuclei of cells
revealed with mAb D3. The images were taken at 100- and 1000-
fold magnification in section A and B, respectively.
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Page 13 of 22using primers for: the matrix metalloproteinases MMP-2
and MMP-9 that in addition to modulation of the
tumor microenvironment play an important role in can-
cer cell migration and even signaling pathways [71], the
metalloproteinase inhibitors TIMP-1 and TIMP-2 [72],
nucleolin that is induced constantly in proliferating
tumor cells to generate surface nucleolin [15], nucleo-
phosmin is another nucleolar protein that also interacts
with Nucant [49], and the housekeeping gene GAPDH
as a control. We found out that MMP-2 is not
expressed in SW620 cells, whereas MMP-9 is expressed
temporally and transiently, since it is expressed at 24
hours after passage of cells but drops completely at 48
hours (Figure 6A). Such variation and temporal expres-
sion of MMP-2 and MMP-9 mRNA in tumor cells has
been reported previously [42,73]. The expression of the
other genes, TIMP-1, TIMP-2, nucleolin, nucleophos-
min, and GAPDH is readily detectable at different days
after cell passage in SW620 cells. The results of a typical
RT-PCR analysis are presented in Figure 6 showing the
expression of various transcripts at 24, 48 and 72 hours
after seeding of SW620 cells in the absence or presence
of 10 μM of N7. Strikingly, Nucant treatment
completely abolished the expression of MMP-9 tran-
scripts observed at 24 hours post-seeding. In addition,
Nucant treatment exerted a marked down regulation
transcripts coding nucleolin at different days after pas-
sage of cells, whereas the expression of transcripts cod-
ing nucleophosmin was not affected (Figure 6A). Nucant
mediated reduction of MMP-9 and nucleolin transcripts
occurs by a dose-dependent manner and by a selective
mechanism, since the expression of the other genes is
not affected (Figure 6B). The molecular mechanism of
such selective down regulation of MMP-9 mRNA might
be the consequence, at least in part, of the marked
down regulation of nucleolin. In this respect, it is of
interest to note that nucleolin present in the cytoplasm
binds 3’-untranslated region in MMP-9 mRNA, a pro-
cess that is necessary for the stability and translational
efficiency of MMP-9 mRNA [4]. Nucleolin-binding to
MMP-9 mRNA increases the production of the enzyme
that by degrading extracellular matrix components pro-
motes tumor metastasis. Expression of MMP-9 is
strongly linked with malignant tumor progression and
metastasis of various types of cancers [71]. Similarly,
expression of nucleolin is highly associated with tumor
cell proliferation and angiogenesis [15]. Consequently,
the selective down regulation of such strategic genes
could account, at least in part, for the inhibitory
mechanism on proliferation and spreading/migration of
such colon carcinoma cells.
Multiplication of T29 lymphoma cells is inhibited by the
multivalent Nucant pseudopeptides due to a selective
mechanism of cell death
In epithelial type tumor cell cultures, HB-19 and Nucant
pseudopeptides could affect cell adhesion (Figure 4),
migration (Additional file 5, Figure S7), spreading (Fig-
ure 5), and restore contact inhibition [38,42](Additional
file 5, Figure S6), but have no significant effect on cell
viability as demonstrated by the lack of trypan blue
uptake in cells at 24 hours after treatment (Table 4, Fig-
ure 4B). In contrast to epithelial cells however, these
pseudopeptides induce cell death in several leukemia
cells (Table 4), in which nucleolin is highly expressed at
the cell surface [15]. The binding and internalization of
pseudopeptides in Leukemia cells result in a selective
down regulation of surface but not nuclear nucleolin in
a dose dependent manner (data not shown), as it is the
case in epithelial cells (Figure 2B, D)[13,37].
Figure 7 presents a typical experiment in T29 lym-
phoma cells to demonstrate the inhibitory action of pen-
tavalent (HB-19, N3) and hexavalent (N6 and N7)
pseudopeptides on the proliferation of leukemia cells,
T29 cells were passaged in the absence or presence of
20 μMa n d1 0μM of pentavalent and hexavalent pseu-
dopeptides, respectively, and cell number was monitored
Figure 6 Selective down regulation of MMP-9 and nucleolin
transcripts in Nucant treated SW620 cells. A. SW620 cells in the
absence (lanes -) and presence (lanes +) of 10 μM of N7 were
cultured for 24, 48, and 72 hours. B. Dose dependent reduction of
MMP-9 and nucleolin transcripts in response to Nucant treatment.
Newly seeded SW620 cells were cultured in the absence (lanes 1)
and presence of 2.5 (lanes 2), 5 (lanes 3) and 10 (lanes 4) 10 μMo f
N6 for 20 hours. Total RNA extracts were prepared at different time
points and the expression of various transcripts was analyzed by RT-
PCR using specific primers (Methods). NCL stands for nucleolin; NPM
stands for nucleophosmin.
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Page 14 of 22daily for 3 days (Figure 7A). At 3 days post passage of
T29 cells, the multiplication index of control cells is
17.5-fold compared to 8.9-, 7.2-, 2.2-, and 1.7-fold in the
presence of treatment with HB-19, N3, N6, and N7,
respectively. Thus the inhibitory activity of hexavalent
pseudopeptides is stronger compared to that of pentava-
lent pseudopeptides, consistent with our previous obser-
vation in HeLa cells (Figure 2A). In order to estimate
the 50% inhibitory concentration (IC50) values of the
different pseudopeptides, we carried out several sets of
experiments in which T29 cells were cultured for several
days in the presence of 2.5, 5, 10, and 20 μMo fe a c ho f
the pentavalent and hexavalent pseudopeptides. A typi-
cal experiment is presented in Figure 7B showing that
the reduction of cell number in response to treatment
with HB-19 and Nucant pseudopeptides occurs in a
dose dependent manner. More importantly, counting
trypan blue positive cells, i.e. cells with permeable mem-
branes, indicated that the reduction of leukemia cell
number is in fact due to cell death. This latter is clearly
demonstrated at high concentrations of pseudopeptide
when viable cell number is reduced drastically as soon
Figure 7 HB-19 and related multivalent Nucant pseudopeptides induce cell death associated with internucleosomal DNA
fragmentation. A. Inhibition of cell multiplication by HB-19 and related multivalent Nucant pseudopeptides. T29 cells at 150,000 cells/ml in 2 ml
of culture medium were seeded (Day 0) in the absence (Control) or presence of 20 μM of pentavalent (HB-19, N3) and 10 μM of hexavalent (N6
and N7) pseudopeptides. Cell cultures (in triplicate) were monitored for viable cell number daily for 3 days. The histograms show the mean
number of cells/ml ± SD of triplicate samples. The multiplication index of cells at day 3 compared to day 0 (the day of seeding) is given at the
top of histogram. At 3 days post passage of T29 cells, the cell multiplication index of cells is 17.5-fold compared to 8.9-, 7.2-, 2.2-, and 1.7-fold in
the presence of treatment with HB-19, N3, N6, and N7, respectively. B. N7 inhibits T29 cell multiplication in a dose dependent manner. T29 cells
seeded at 100,000/ml in 2 ml in the absence (0 μM) or presence of N7 at various concentrations 2.5, 5, 10 and 20 μM were cultured for 3 days
and the number of viable cells was determined at day 1, 2, and 3 post-seeding. The ordinate gives the cell number/ml (the mean of 2 samples)
in each culture at day 1, 2, and 3 post-seeding. C. Partial cleavage of surface/cytoplasmic nucleolin. T29 cells were cultured for 45 min with 0 (for
control; lanes C), 2 and 10 μM of N6 before preparation of cytoplasmic (that contains both surface and cytoplasmic nucleolin) and nuclear
extract and analysis by immunoblotting using rabbit polyclonal antibodies that are directed against the first 26 (panel anti-Nt Ab) and the last 16
amino acids (panel anti-Ct Ab) of human nucleolin, respectively. The nuclear extracts were analyzed by immunoblotting using anti-Nt Ab
(Methods). The cleavage products, p60 and p70, are revealed with the anti-Ct Ab only. D. Internucleosomal DNA cleavage in Nucant treated
Cells. T29 cells, untreated (lane 0) or treated at 2.5, 5, 10, and 20 μM of N6, or 10 μg/ml of cycloheximide (CHX) or 20 μM of bisphosphonate
(BisP) for 24 hours, were processed for extraction of the low molecular weight DNA from the nucleoplasm (Methods). Lane M shows the
electrophoresis mobility of the DNA marker composed of a 100 base-pair ladder. On the right is the position of nucleosomal fragments, starting
from the monomer, dimer, trimer and tetramer unit of 180, 360, 540, and 720 bp, respectively. Statistical significance: *p < 0.1, **p < 0.01, ***p <
0.001.
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Page 15 of 22as 24 hours post-treatment, thus revealing the occur-
rence of cell death (for an example see Figure 7B at 20
μM of N7). Although there were some slight variations
in the IC50 values from one experiment to the other,
consistently the results indicated that the hexavalent
pseudopeptides manifest several fold higher inhibitory
activity compared to the pentavalent pseudopeptides.
Table 7 gives the IC50 values for the various pseudo-
peptides in respect to their capacity to induce cell death
and inhibit cell proliferation at 24 and 72 hours, respec-
tively. Among the hexavalent Nucant pseudopeptides,
N6L exerts 2 to 4 fold higher activity compared to that
of its counterparts, N6 and N7. This is most probably
due to its stable structure, since it presents the pseudo-
tripeptide Lysψ(CH2N)-Pro-Arg all in L configuration
(Table 1, Methods).
Like in other cell types [15], surface/cytoplasmic
nucleolin in T29 cells is degraded selectively upon treat-
ment of cells with the Nucant pseudopeptides, since
degradation of surface/cytoplasmic nucleolin occurs
without any apparent effect on the level of nuclear
nucleolin (Figure 7C). Interestingly, rabbit polyclonal
antibodies directed against the last 16 but not the first
26 amino acid residues of nucleolin reveal the presence
of partial cleavage products of 70- and 60-kDa (referred
to as p70 and p60), thus indicating that such cleavage
fragments are derived from the COOH-terminal end of
nucleolin. Finally, we investigated whether Nucant-
mediated cell death in leukemia cells is associated with
internucleosomal DNA fragmentation (Figure 7D). No
low molecular weight DNA fragments are observed in
the nucleoplasm of control cells, whereas there is a
Nucant-dose dependent increase of DNA fragments
with a characteristic internucleosomal DNA cleavage
ladder-pattern, generally observed in cells undergoing
programmed cell death (PCD). A similar profile of DNA
fragments was observed in cells treated with the anti-
cancer drug bisphosphonate or the protein synthesis
inhibitor cycloheximide [74], which are known to induce
apoptosis.
In contrast to our results observed in MDA-MB 231
cells (Additional file 4, Figure S5), Nucant pseudopep-
tides were recently reported to be internalized and
translocated into the nuclei of MDA-MB 231 cells [49].
In view of this and of the Nucant-induced cell death in
leukemia cells, we investigated the entry of biotinylated
N3 and N7 in the human leukemia HuT 78 cells. For
this purpose HuT 78 cells were incubated (37°C, 5
hours) with 15 μM concentration of the biotinylated N3
and N7 construct, before PFA/Triton fixation and pro-
cessing for immunofluorescence microscopy. Figure 8A
and 8B indicate that most of the signal is located in the
cytoplasm, with almost no signal in the nuclei. Conse-
quently, we believe that the reported nuclear transloca-
tion of Nucant [49] is an artifact due to the
experimental conditions that were used to fix cells.
Indeed, Destouches et al have fixed cells with methanol/
acetone, which appear to permeabilize the nuclear mem-
brane and modify localization of Nucant during fixation
of cells. Accordingly, when biotinylated N7 treated HuT
cells were fixed with methanol/acetate, and then the
entire signal was found to be localized in the nuclei of
cells (Figure 8C).
The fact that Nucant does not affect cell viability in
epithelial tumor cells indicates that the capacity of
Nucant to induce cell death in leukemia cells is by a
selective mechanism rather than due to non-specific cel-
lular injury. The pathway by which Nucant induces cell
death and the type of PCD remains to be investigated.
The early loss of plasma membrane integrity in different
types of leukemia cells in response to Nucant treatment
favors necrotic type of PCD, since plasma membrane
integrity is preserved during PCD by apoptosis in spite
of internucleosomal DNA fragmentation [51,75]. Intri-
guingly, Nucant induced early loss of plasma membrane
integrity is associated with internucleosomal cleavage of
cellular DNA with the characteristic ladder pattern,
which is generally observed in cells undergoing apopto-
sis. Previously, internucleosomal DNA cleavage, visua-
lized as ladders, has been reported during necrosis in
Table 7 IC50 values for the induction of cell death and reduction of cell number in T29 cells treated with HB-19 and
related multivalent pseudopeptides
Pseudopeptide (Multivalent) Cell death: IC50 24 hours post-passage Cell number: IC50 72 hours post-passage
HB-19 (pentavalent) > 20 μM2 0 μM
N3 (pentavalent) > 20 μM5 μM
N6 (hexavalent) 20 μM8 μM
N7 (hexavalent) 20 μM8 μM
N6L (hexavalent) 5-10 μM 2-4 μM
T29 cells were passaged in the presence of HB-19, N3, N6, N7, and N6L at various concentrations 0, 2.5, 5, 10 and 20 μM for 3 days. Twenty-four hours after the
treatments, cell death was monitored by the uptake of trypan blue. The number of viable cells at 3 days post-treatment was used to estimate the IC50 values for
the reduction of cell number. The pseudopeptides represent pentavalently or hexavalently the pseudo-tripeptide Lysψ(CH2N)-Pro-Arg (Figure 1).
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Jurkat and MDCK cells [76].
Nucant pseudopeptides bind surface nucleolin at a higher
affinity compared to binding to nucleophosmin
Recently, by using the biotinylated Nucant construct, N6L,
Destouches et al have reported that the recovery the cell
surface nucleolin results in the copurification of several
other proteins, including SRP68, SRP72, ribosomal pro-
teins, and nucleophosmin [49]. As we did not recover
nucleophosmin in our initial experiments using the bioti-
nylated HB-19 (Table 2 and 3), two biotinylated Nucant
constructs were used here for the recovery of surface
nucleolin and nucleolin-associated proteins: the pentava-
lent N3 pseudopeptide that has a similar Aib contain tem-
plate as N6L, and the hexavalent N7 pseudopeptide that
has a similar template as HB-19 (Table 1). We first
demonstrated that maximum binding to the surface
nucleolin on MDA-MB 231 cells occurred at 5 and 3 μM
concentration of the biotinylated N3 and N7, respectively
(data not presented). Material purified from the surface of
such cells was then analyzed by SDS-PAGE, before stain-
ing the pattern of the purified proteins and immunoblot-
ting using anti-nucleolin or anti-nucleophosmin
antibodies (Figure 9A). Both biotinylated N3 and N7 pseu-
dopeptides resulted in the recovery of a similar pattern of
proteins, including nucleolin as expected but not nucleo-
phosmin. In another experiment we used T cell leukemia
HuT 78 cells in which the Nucant pseudopeptide induces
cell death (Table 4). As expected, the biotinylated N7 was
found to bind nucleolin expressed on the surface of HuT
78 cells in a dose dependent manner, with maximum
binding at 4 μM concentration. On the other hand,
nucleophosmin binding occurred only at the highest
Figure 9 Nucant pseudopeptides bind surface nucleolin at a
higher affinity compared to binding to nucleophosmin.A .
Recovery of surface nucleolin and associated proteins by using
biotinylated Nucant. MDA-MB 231 cells were incubated in the
absence (lanes Control) or presence of 6 μM biotinylated N3 (N3/
Biot.) or 4 μM of N7 (N7/Biot.) for the recovery of surface nucleolin
and associated proteins under similar experimental conditions as
described in the case of HB-19/Biot. (Methods). Purified material was
then analyzed by SDS-PAGE and stained with Brilliant Blue G-
Colloidal Concentrate staining (panel Staining). Similar samples were
also analyzed by immunoblotting using anti-nucleolin mAb D3
(panel anti-nucleolin) or anti-nucleophosmin mAb EP1848Y (panel
anti-nucleophosmin)(Methods). B. Nucant binds nucleophosmin
independently of its capacity to bind to surface nucleolin. The T-cell
leukemia HuT 78 cells were incubated at 0, 1, 2, 4, and 8 μM of the
biotinylated N7 for the recovery of surface nucleolin and associated
proteins. Nucleolin and nucleophosmin were revealed by
immunoblotting as above.
Figure 8 Nucant pseudopeptides are internalized into cells and
accumulate in the cytoplasm without translocation to the
nucleus. A/B. HuT 78 cells in polylysine-coated eight-well glass
slides were incubated (37°C) with 15 μM of biotinylated N3 or N7
for 5 hours before PFA/Triton fixation and processing for
immunofluorescence microscopy using rabbit anti-biotin and FITC
conjugated goat anti-rabbit IgG. C. HuT 78 cells in polylysine-coated
slides were incubated (37°C) with 15 μM of biotinylated N7 for 5
hours before methanol/acetate fixation and processing for
immunofluorescence microscopy as in A/B (Methods). The nuclei
stained with DAPI are shown on the right of each panel. Treatment
of HuT 78 cells at 15 μM of biotinylated N3 or N7 leads to 25 and
40% cell death after 24 of culture, respectively.
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μM concentration; Figure 9B). These results indicate that
Nucant binds nucleophosmin independently of its capacity
to bind to surface nucleolin. Moreover, the binding affinity
of Nucant to nucleophosmin is much lower compared to
its binding affinity to surface nucleolin. These observations
suggest that nucleophosmin is not one of the protein com-
ponents of the 500-kDa complex. Consistent with this,
Nucant is shown to bind nucleophosmin in solution [49].
Consequently, nucleophosmin represents an additional
target of Nucant pseudopeptides (Table 8).
Like nucleolin, nucleophosmin is a nucleo-cytoplasmic
shuttling multifunctional protein with prominent
nuclear localization. It is involved in many cellular pro-
cesses, including the transport of pre-ribosomal particles
and ribosome biogenesis, the response to stress stimuli,
the maintenance of genomic stability, regulation of
DNA transcription, and regulation of crucial tumor sup-
pressors such as p53 and ARF [77]. The expression of
nucleophosmin at the cell surface, and its implication in
the overall mechanism of action of Nucant pseudopep-
tides against various tumor cell types remain to be char-
acterized. Nevertheless, nucleophosmin and nucleolin
expressed at the cell surface interact with K-Ras, and
play a critical role in signal transduction via the MAPK
pathway [25]. In general nucleophosmin appears to be
relatively stable compared to the expression of surface
nucleolin, which is constantly induced in association
with the proliferative state of tumor cells [15].
Conclusions
HB-19 and related multivalent Nucant pseudopeptides
are potent antitumoral agents by their capacity to exert
multiple and distinct inhibitory effects
By their capacity to bind surface nucleolin in the 500-
kDa protein complex, we show that HB-19 and related
multivalent Nucant pseudopeptides exert multiple and
distinct inhibitory effects on cell proliferation, adhesion,
spreading, inflammation, and cell death. This is a unique
property of HB-19 and related Nucant pseudopeptides,
since other antitumoral agents do not exert a differential
mode of action depending on a given tumor cell type. In
addition to surface nucleolin, HB-19 and related Nucant
pseudopeptides at high concentrations can bind directly
other proteins expressed on the cell-surface, such as
nucleophosmin [49] and the putative HLA class II-asso-
ciated protein PHAP I and PHAP II [8](Table 8).
The official name of PHAP I and PHAP II is ANP32A
for the acidic nuclear phosphoprotein 32 family member
A, and the SET nuclear oncogene, respectively. Both
ANP32A and SET have been described by several
groups who have named them according to a specific
function (Table 8). Like nucleolin, ANP32A and SET
are nucleo-cytoplasmic shuttling phosphoproteins with
various functions in cell metabolism. The common fea-
tures between ANP32A and SET are the presence of an
acidic carboxyl-terminal tail, association with HLA class
II molecules, protein phosphatase 2 inhibitory activity,
histone acetyltransferase inhibitory activity, and implica-
tion in mechanisms initiating cell death [78-81]. Conse-
quently, Nucant-mediated occurrence of cell death in
leukemia cells might be associated, at least in part, with
the functioning of ANP32A and SET. In this respect, it
is worthwhile to note that cross-linking of HLA class II
has been reported to induce caspase independent cell
death in lymphocytes [82]. Moreover, engagement of
class II molecules mediates the transduction of signals
leading to cell death, which is associated with the
enhanced expression of IL-1b and TNF-a mRNA
[83,84].
Several reports have now provided evidence that sur-
face nucleolin is a promising target for cancer therapy
Table 8 The capacity of HB-19 and related multivalent Nucant pseudopeptides to bind ANP32A
1, SET
1, and
nucleophosmin
2 expressed on the cell surface of cells in addition to nucleolin.
ANP32A: The acidic nuclear phosphoprotein 32 family, member A. In the literature it has also been referred to as LANP, MAPM, PP32, PHAP I,
I1PP2A, C15orf1, MGC119787, and MGC150373. ANP32 is a 30-kDa phosphoprotein that is mainly described in the nucleus. It is characterized by an
N-terminal tandem arrays of a leucine rich repeat and an acidic carboxyl half. ANP32A is implicated in a number of cellular processes, including
modulation of cell signaling and transduction of gene expression to regulate the morphology and dynamics of the cytoskeleton, cell adhesion and
differentiation, and caspase-dependent and caspase-independent apoptosis [78].
SET nuclear oncogene. In the literature it has also been referred to as 2PP2A, IGAAD, TAF-I, I2PP2A, IPP2A2, PHAP II, and TAF-IBETA. SET is a 39-kDa
phosphoprotein with a highly acidic carboxyl-terminus. It is a multifunctional protein widely expressed in various tissues and localizes predominantly
in the nucleus. It is involved in apoptosis, transcription, nucleosome assembly and histone binding [79].
Nucleophosmin. Also referred to as B23, nucleophosmin is a 37-kDa protein ubiquitously expressed chaperone that shuttles rapidly between the
nucleus and cytoplasm, but predominantly resides in the nucleolus [101]. It is implicated in several cellular processes, including ribosome biogenesis,
centrosome duplication, cell cycle progression, and apoptosis [77]. Somatic mutations in the exon 12 of the nucleophosmin gene (NPM1) are the
most frequent genetic abnormality in adult acute myeloid leukemia leading to aberrant localization of nucleophosmin into the cytoplasm [77,101],
which might be a critical event for leukogenesis [102].
1 At concentrations ≥ 10 μM, HB-19 binds ANP32A (PHAP I) and SET (PHAP II) in addition to nucleolin expressed on the surface of cells [8].
2 Nucant binds nucleophosmin at concentrations: ≥ 8 μM of N7 (in Figure 9), and at a concentration of N6L that was not stated in the article by Destouches et al
[49].
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Page 18 of 22[37,38,40,85,86]. Chemotherapy by targeting surface
nucleolin could be less toxic compared to conventional
cancer drugs, since nucleolin is continuously and
abundantly expressed in tumor compared to normal
cells, thus making tumor cells the preferential targets
of inhibitors of surface nucleolin [15]. Another para-
meter that could contribute to the lack of toxicity is
the capacity of HB-19 and related Nucant pseudopep-
tides to block the functioning of surface nucleolin
without affecting nuclear nucleolin, which controls
many aspects of cellular metabolism [1,3,15,37,38].
Indeed, after specifically binding to surface nucleolin,
HB-19 and related Nucant pseudopeptides enter cells
and accumulate in the cytoplasm without crossing the
nuclear membrane. Consequently, the effect of these
nucleolin antagonists is exerted differentially via the
cell surface expressed nucleolin without affecting
nuclear nucleolin.
The fact that nucleolin has several protein partners at
the cell-surface, and the capacity of HB-19 and related
Nucant pseudopeptides to bind additional cell surface
proteins besides nucleolin, suggest that the response of
tumor cells to these multivalent pseudopeptides should
be associated with the expression and/or the level of
surface nucleolin and the different nucleolin-partners in
tumor cells. Consequently, these surface nucleolin
antagonist pseudopeptides exert distinct inhibitory
mechanisms depending on a given tumor cell type.
Taken together, our results indicate that HB-19 and
r e l a t e dN u c a n tp s e u d o p e p t i d e sr e p r e s e n tau n i q u e
multi-action drug, which provides novel therapeutic
opportunities in treatment of a wide variety of cancers
and related malignancies.
Additional material
Additional file 1: The molecular structure of Nucant
pseudopeptides, N3, N6, and N7. N3 and N6 respectively present the
pseudo-tripeptide Lysψ(CH2N)-Pro-Arg pentavalently and hexavalently,
they are coupled to a polypeptide template containing Aib. N7 presents
hexavalently the pseudo-tripeptide Lysψ(CH2N)-Pro-Arg coupled to a
template similar to that of HB-19 (Figure S1).
Additional file 2: PAGE-SDS analysis of proteins associated with the
cell surface expressed nucleolin in the 500-kDa complex. The
capacity of HB-19 to bind specifically surface nucleolin provides a
convenient method to recover the nucleolin associated proteins, which
were identified by microsequencing of their NH2-terminal ends (Figure
S2).
Additional file 3: A potential candidate for a transmembrane
protein partner of the cell surface expressed nucleolin is the low-
density lipoprotein (LDL) receptor related protein (LRP1). In Chinese
hamster ovary CHO LRP1-null cells, although nucleolin is present
abundantly in the nucleus and in the cytoplasm, it remains undetectable
at the cell surface (Figure S3). Consequently, in the absence of surface
nucleolin in such LRP1-null cells, ligands of nucleolin are internalized by
a receptor-independent passive process (Figure S4).
Additional file 4: Nucant pseudopeptides do not translocate into
the nucleus. Like other surface nucleolin ligands, HB-19 and related
Nucant pseudopeptides enter cells by an active process and become
accumulated in the cytoplasm without translocating to the nuclei (Figure
S5). The recent report on nuclear translocation of N6L might be an
artifact due to the experimental conditions in which cells were fixed with
methanol/acetone.
Additional file 5: N6L treatment restores contact inhibition and
reduces the motility of human breast cancer cells. Treatment of
MDA-MB 435 cells with Nucant leads to restoration of contact inhibition,
while corresponding control tumor cells proliferate without contact
inhibition by piling up over each other (Figure S6). In a wound-healing
assay, invasion of the scratched area occurs much more freely in the
untreated compared to N6L treated cell culture (Figure S7).
Abbreviations
HB-19: the surface-nucleolin antagonist-pseudopeptide that presents
pentavalently the tripeptide Kψ(CH2N)PR; HB-19/Btn: biotinylated HB-19;
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